Prophylactic cefixime and prulifloxacin for ultrasound-guided prostate biopsy


  • Mary Corcoran
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Prophylactic cefixime and prulifloxacin are effective in preventing acute bacterial sepsis after transrectal ultrasound-guided prostate biopsy, according to findings from a new trial presented at the 34th Annual European Association of Urology Congress in Barcelona this month. 

For the trial, 120 patients aged 51-87 (mean 68.6) years and with a prostate-specific antigen value of 5.08-100 (mean 13.86) ng/mL were prospectively divided into two groups of 60 patients. Group A received a three-day regimen of cefixime 400 mg p.o/day, while group B received three days of prulifloxacin 600 mg p.o/day. Treatment commenced a day before the procedure and patients were followed up for symptoms for seven days post-biopsy.

Sixteen of the men had previously underwent a biopsy, while 18 patients had received prulifloxacine and eight had received cefixime at least once in the last three months. 

During follow-up, 97.5 per cent of patients did not present with urinary tract infection post-biopsy.

Hospital admission because of septicaemia was required in 1.2 per cent of patients in group B and 0.6 per cent of patients in group A. The bacteria detected in these urine cultures were resistant to prulifloxacin and cefixime, while a history of use was noticed. 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit